Scientists test supercharged immune cells against stubborn blood cancer
NCT ID NCT06203912
Summary
This early-stage study is testing a new combination treatment for multiple myeloma that has come back or stopped responding to other therapies. It combines a lab-modified version of a patient's own immune cells (called TiNK cells) with a drug called isatuximab, along with standard chemotherapy. The main goal is to find a safe dose and understand the side effects in a small group of patients who have already tried many other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.